AgeX Therapeutics, Inc. (AGE)

AgeX Therapeutics, Inc. (AGE) Healthcare & Pipeline Overview

AgeX Therapeutics, Inc. is a clinical-stage biotechnology company pioneering cell and gene therapies for age-related metabolic and degenerative diseases. Utilizing induced Tissue Regeneration (iTR™) technology, the company develops candidates like AGEX-BAT1 for diabetes and AGEX-VASC1 for ischemic tissues, addressing significant unmet medical needs in the healthcare sector.

What Is the Investment Thesis for AGE?

AgeX Therapeutics, Inc. presents an investment profile centered on its innovative pipeline targeting age-related degenerative diseases, a sector with substantial unmet medical needs and significant growth potential driven by an aging global population. The company’s core value drivers include its proprietary induced Tissue Regeneration (iTR™) technology and its diverse therapeutic candidates, such as AGEX-BAT1 for metabolic disorders and AGEX-VASC1 for ischemic tissues. Key growth catalysts are tied to the successful advancement of these candidates through pre-clinical and clinical development stages, which could validate the technology and attract further investment or partnerships. However, as an early-stage biotechnology company with a market capitalization of $27.76M, AgeX Therapeutics faces considerable risks. The company reported a profit margin of -16359.2%, indicating significant ongoing losses typical of R&D-intensive firms. Its Beta of 1.19 suggests higher volatility compared to the broader market. Future financing activities and the ability to navigate complex regulatory pathways for novel cell and gene therapies will be critical determinants of its long-term viability and potential for commercialization.

Based on FMP financials and quantitative analysis

AGE Key Highlights

• Market capitalization of $27.76M, positioning AgeX Therapeutics as a micro-cap biotechnology company.
• Gross margin of 73.8%, reflecting potential efficiency in its research and development operations despite overall unprofitability.
• Profit margin of -16359.2%, highlighting significant net losses consistent with an early-stage biotech firm investing heavily in R&D.
• Beta of 1.19, indicating higher stock price volatility relative to the overall market, common for clinical-stage biotechnology companies.
• Focused pipeline on cell and gene therapies for age-related metabolic and degenerative diseases, addressing a growing demographic need.

Who Are AGE's Competitors?

AGE is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are AGE's Key Strengths?

• Innovative induced Tissue Regeneration (iTR™) technology platform with broad potential applications.
• Focused pipeline addressing significant unmet medical needs in age-related metabolic and degenerative diseases.
• Diverse therapeutic modalities under development, including cell-based, drug-based, and biologic candidates.
• Strategic research collaboration with the University of California at Irvine for neurological disorders.

What Are AGE's Weaknesses?

• Small market capitalization of $27.76M, indicating limited financial resources compared to larger competitors.
• Significant unprofitability, with a profit margin of -16359.2%, typical of early-stage R&D-intensive companies.
• Pipeline primarily in early development or discovery stages, with no products currently on the market.
• Very small employee base of 4, potentially limiting the pace and scale of operations.

What Could Drive AGE Stock Higher?

• Initiation or significant advancement of clinical trials for AGEX-BAT1, a cell therapy for age-related metabolic disorders.
• Initiation or significant advancement of clinical trials for AGEX-VASC1, a cell-based therapy for ischemic tissues.
• Public announcement of key pre-clinical data or progress in the discovery phase for AGEX-iTR1547 or AGEX-iTR1550.
• Continued research collaboration activities with the University of California at Irvine for developing cellular therapies for neurological disorders.
• Successful securing of additional financing rounds or strategic partnerships to fund ongoing research and development efforts.

What Are the Key Risks for AGE?

• Financial-distress signal — its Altman Z-Score of -3.08 sits in the distress zone (elevated bankruptcy risk).
• Significant operating losses and negative profit margin (-16359.2%) due to high research and development expenses, requiring continuous external funding.
• Clinical trial failures or unexpected delays for lead candidates like AGEX-BAT1 and AGEX-VASC1, which could halt development and impact valuation.
• Inability to secure adequate future funding, which is critical for sustaining long-term research and development activities in the biotechnology sector.
• Intense competition within the biotechnology industry, particularly in the rapidly evolving fields of regenerative medicine and age-related therapies.
• Regulatory approval challenges, as novel cell and gene therapies face stringent and complex review processes by health authorities like the FDA.

What Are the Growth Opportunities for AGE?

• Advancement of AGEX-BAT1 for Metabolic Disorders: The successful progression of AGEX-BAT1, a cell therapy product candidate for Type II adult-onset diabetes and obesity, represents a significant growth opportunity. The global market for diabetes treatment alone is projected to be hundreds of billions of dollars, with obesity also representing a massive and growing health crisis. Advancing AGEX-BAT1 through clinical trials and demonstrating efficacy could unlock substantial market potential, offering a novel therapeutic approach to these widespread age-related metabolic conditions. The timeline for such development is typically several years, contingent on clinical trial success and regulatory approvals.
• Advancement of AGEX-VASC1 for Ischemic Tissues: AGEX-VASC1, a cell-based therapy designed to restore vascular support in aged ischemic tissues, targets critical conditions such as peripheral vascular disease and ischemic heart disease. These conditions affect millions globally and often lack fully effective long-term treatments, representing a substantial unmet medical need. The market for cardiovascular disease treatments is vast, estimated to be in the hundreds of billions. Successful clinical development and commercialization of AGEX-VASC1 could provide a transformative therapy, establishing AgeX Therapeutics as a leader in vascular regeneration. This opportunity is also subject to multi-year clinical and regulatory timelines.
• Leveraging the Induced Tissue Regeneration (iTR™) Technology Platform: The company's iTR™ technology, exemplified by candidates like AGEX-iTR1547 for scarless wound repair and AGEX-iTR1550 for induced tissue regeneration, offers a broad platform for future growth. This technology has the potential for wide applicability across various degenerative conditions and tissue repair needs beyond the current pipeline. Successfully validating the platform through initial candidate development could attract further investment, partnerships, and enable the expansion into new therapeutic areas, thereby diversifying the company's revenue streams and reducing reliance on single product success. The long-term potential of this platform is significant.
• Strategic Collaborations and Partnerships: AgeX Therapeutics currently has a research collaboration with the University of California at Irvine for neurological disorders. Expanding upon this model, securing additional strategic partnerships with larger pharmaceutical companies or academic institutions could significantly accelerate the development and commercialization of its pipeline candidates. Such collaborations can provide crucial funding, access to advanced research capabilities, and established commercialization infrastructure, mitigating the financial and operational risks inherent in early-stage biotech. These partnerships could also validate the scientific merit of AgeX's technology, enhancing its market position.
• Expansion into New Therapeutic Areas: Beyond its current focus on metabolic disorders, ischemic tissues, and wound repair, the versatility of AgeX Therapeutics' iTR™ technology platform presents opportunities to explore and develop therapies for other degenerative diseases. As research progresses and the understanding of tissue regeneration deepens, the company could identify new applications for its technology in areas such as neurodegeneration, musculoskeletal repair, or organ regeneration. This strategic diversification would broaden its addressable market and reduce dependency on the success of a limited number of pipeline assets, offering long-term growth potential.

What Opportunities Does AGE Have?

• Successful advancement of lead candidates (AGEX-BAT1, AGEX-VASC1) through clinical trials, validating the technology.
• Expansion of the iTR™ technology platform into new therapeutic areas beyond current pipeline indications.
• Formation of additional strategic partnerships or licensing agreements to secure funding and accelerate development.
• Capitalizing on the growing global demand for innovative therapies for an aging population and chronic diseases.

What Threats Does AGE Face?

• High risk of clinical trial failures or significant delays for pipeline candidates.
• Intense competition from established pharmaceutical companies and other biotechnology firms in regenerative medicine.
• Challenges in securing adequate future funding to support long and costly R&D cycles.
• Complex and evolving regulatory approval processes for novel cell and gene therapies.
• High stock price volatility, as indicated by a Beta of 1.19, potentially impacting investor confidence and financing.

What Are AGE's Competitive Advantages?

• Proprietary induced Tissue Regeneration (iTR™) technology platform, offering a unique approach to cellular and tissue repair.
• Specialized focus on cell and gene therapies for human aging and degenerative diseases, addressing complex biological pathways.
• Early-stage pipeline addressing significant unmet medical needs in large and growing therapeutic markets.
• Established research collaboration with the University of California at Irvine, leveraging academic expertise and resources.

What Does AGE Do?

AgeX Therapeutics, Inc., incorporated in 2017 and headquartered in Alameda, California, is a biotechnology company dedicated to the development and commercialization of novel therapeutics. The company's primary focus is on addressing human aging and degenerative diseases within the United States market. Its strategic approach centers on innovative cell and gene therapy platforms, including its proprietary induced Tissue Regeneration (iTR™) technology, designed to tackle significant unmet medical needs. The company's pipeline features several key therapeutic candidates. AGEX-BAT1 is a lead cell therapy product candidate specifically designed for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity, representing a substantial market opportunity given the global prevalence of these conditions. Another prominent cell-based therapy in development is AGEX-VASC1, which aims to restore crucial vascular support in aged ischemic tissues, targeting debilitating conditions like peripheral vascular disease and ischemic heart disease. Beyond cell therapies, AgeX Therapeutics is also advancing drug-based and biologic candidates. AGEX-iTR1547 is a lead drug-based formulation in the discovery phase, focused on scarless wound repair, an area with significant clinical demand. Additionally, AGEX-iTR1550 is a lead biologic candidate utilizing gene delivery technology for induced tissue regeneration. The company further expands its research capabilities through a collaboration with the University of California at Irvine, jointly working on developing cellular therapies for neurological disorders and diseases. With a lean operational structure, comprising four employees, AgeX Therapeutics, Inc. maintains a concentrated research and development effort typical of early-stage biotechnology firms.

What Products and Services Does AGE Offer?

• Develops novel therapeutics targeting human aging processes.
• Focuses on treatments for various degenerative diseases.
• Advances cell-based therapeutic candidates like AGEX-BAT1 for metabolic disorders.
• Develops cell-based therapies such as AGEX-VASC1 for ischemic tissues.
• Explores drug-based formulations, including AGEX-iTR1547 for scarless wound repair.
• Utilizes gene delivery technology for biologic candidates like AGEX-iTR1550 for tissue regeneration.
• Engages in research collaborations, notably with the University of California at Irvine for neurological disorders.
• Aims to commercialize its therapeutic pipeline in the United States.

How Does AGE Make Money?

• Primarily focused on the research and development of novel therapeutic candidates for age-related and degenerative diseases.
• Aims to commercialize approved therapies, generating revenue from product sales post-regulatory approval.
• May pursue licensing agreements or strategic partnerships for its pipeline assets to secure funding and accelerate development.
• Relies on external funding, such as equity financing or grants, to support its extensive research and development expenditures given its early stage and unprofitability.

What Industry Does AGE Operate In?

AgeX Therapeutics, Inc. operates within the highly dynamic and research-intensive Biotechnology industry, a sub-sector of Healthcare. This industry is characterized by significant R&D investment, long development cycles, and substantial regulatory hurdles. The company's focus on human aging and degenerative diseases positions it within a rapidly expanding market segment driven by an aging global population and the increasing prevalence of chronic conditions like Type II diabetes, obesity, and cardiovascular diseases. The broader market for regenerative medicine and cell/gene therapies is experiencing robust growth, with continuous scientific advancements and increasing investment. AgeX Therapeutics differentiates itself through its proprietary induced Tissue Regeneration (iTR™) technology and its specific pipeline candidates, aiming to carve out a niche in areas with high unmet medical needs. The competitive landscape is intense, featuring numerous large pharmaceutical companies, established biotechs, and other early-stage innovators vying for market share and intellectual property in these lucrative therapeutic areas.

Who Are AGE's Key Customers?

• Ultimately, patients suffering from age-related metabolic disorders like Type II diabetes and obesity.
• Patients afflicted with ischemic tissues, including those with peripheral vascular disease and ischemic heart disease.
• Healthcare providers, hospitals, and medical institutions that would prescribe or administer AgeX Therapeutics' approved therapies.
• Potential pharmaceutical or biotechnology partners interested in licensing or co-developing its innovative therapeutic candidates.

AgeX Therapeutics, Inc. (AGE) Valuation Context

Valued at $27.76M, AGE is classified as a micro-cap stock. Relative to its peer group, AGE's quantitative score of 68/100 is roughly in line with the peer average of 76/100.

AGE Revenue & Earnings Trend

In Q1 2026, AGE generated $0 in top-line revenue. The company recorded a net loss of $6.9M, with diluted EPS of $-0.58. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, AGE averaged $-0.50 in diluted EPS.

Company Profile

AgeX Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Alameda, US. The company is led by CEO Eun-Jae Park CPA. AGE has traded publicly since 2018.

Key Financial Metrics

Return on assets is -77.9%, showing how much profit it generates from its asset base. Its free cash flow yield is -90.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 4.18 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -94.9%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 4/9Financial Health

AgeX Therapeutics, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -3.08 places it in the distress zone, a signal of elevated financial risk.

Net sellingInsider Activity

The most recent 12 insider filings for AgeX Therapeutics, Inc. break down as 7 sales and 5 purchases. On net that is roughly 13.8M shares disposed (about $1.2M), a signal worth weighing alongside the fundamentals.

AGE Financials

AGE Latest News

No recent news available for AGE.

AGE Analyst Consensus

AGE MoonshotScore

AgeX Therapeutics, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources